Colorescience – makers of the “all-on-one” makeup that combines makeup, skincare and sun care –   announced it has completed a $15 million Series B preferred stock offering.

And the price?  $1.14 per share, which is a 20% increase from its last round. The Series B round was lead by Longwood Fund with existing investors contributing $7.5 million.   

Mary Fisher, Chief Executive Officer of Colorescience, commented:

“We continue to be encouraged by the support of our Board and investors, and are very pleased to add a seasoned executive, Rich Aldrich of the Longwood Fund, to our Board of Directors.”
Aldrich has  co-founded and helped build several successful biotech companies, including Sirtris Pharmaceuticals (acquired by GlaxoSmithKline in 2008) and Concert Pharmaceuticals.